stoxline Quote Chart Rank Option Currency Glossary
  
BioMarin Pharmaceutical Inc. (BMRN)
85.75  0.73 (0.86%)    06-18 11:55
Open: 85.08
High: 86.125
Volume: 648,633
  
Pre. Close: 85.02
Low: 84.96
Market Cap: 16,282(M)
Technical analysis
2024-06-18 11:18:39 AM
Short term     
Mid term     
Targets 6-month :  100.59 1-year :  117.49
Resists First :  86.12 Second :  100.59
Pivot price 80.73
Supports First :  78.43 Second :  73.68
MAs MA(5) :  84.58 MA(20) :  79.53
MA(100) :  85.05 MA(250) :  87.74
MACD MACD :  1.1 Signal :  0
%K %D K(14,3) :  91.4 D(3) :  89.5
RSI RSI(14): 66.6
52-week High :  99.55 Low :  73.68
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BMRN ] has closed below upper band by 17.9%. Bollinger Bands are 79.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 85.62 - 86.04 86.04 - 86.47
Low: 82.07 - 82.51 82.51 - 82.95
Close: 84.31 - 85.01 85.01 - 85.71
Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Headline News

Sun, 16 Jun 2024
Scarborough Advisors LLC Invests $71000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Sat, 15 Jun 2024
Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Declines By 18.7% - MarketBeat

Sat, 15 Jun 2024
Teachers Retirement System of The State of Kentucky Sells 13,897 Shares of BioMarin Pharmaceutical Inc. (NASDAQ ... - MarketBeat

Tue, 11 Jun 2024
BioMarin's Rare Disease Portfolio, Led by Voxzogo, Supports a Narrow Moat - Morningstar

Sat, 01 Jun 2024
An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued - Simply Wall St

Tue, 14 May 2024
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 190 (M)
Shares Float 188 (M)
Held by Insiders 0.8 (%)
Held by Institutions 100.9 (%)
Shares Short 3,740 (K)
Shares Short P.Month 3,690 (K)
Stock Financials
EPS 1.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 26.73
Profit Margin 8.3 %
Operating Margin 12 %
Return on Assets (ttm) 1.7 %
Return on Equity (ttm) 4.2 %
Qtrly Rev. Growth 8.8 %
Gross Profit (p.s.) 0
Sales Per Share 13
EBITDA (p.s.) 1.54
Qtrly Earnings Growth 72.1 %
Operating Cash Flow 280 (M)
Levered Free Cash Flow 64 (M)
Stock Valuations
PE Ratio 80.77
PEG Ratio 1
Price to Book value 3.2
Price to Sales 6.58
Price to Cash Flow 58.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android